very interesting new idea brought to my attention by RHPS today.

http://www.phosphagenics.com/ is the company website and

www.cohenresearch.com has an interesting report on them

with new phosphorylation techniques (inserting a phosphate group into the chemical structure to make it much more readily absorbed into the body), they aim to deliver more effectively previously hard to transmit drugs to the body - Vitamin E (already successfully launched in US), morphine (much smaller amounts needed, so fewer side effects), and others

talks with FDA started on basis of an enhanced delivery rather than enhanced drug action - much simpler process

recently gained Aus government grant of Aus$1.7 to fund Phase I and Pre-Phase II human trials of transdermal morphine delivery

a Material Evaluation Agreement signed with major US pharma to apply PSG's technology to its patented systems

forward PE of 0.54 (yes I did get the decimal point in the right place!)

shares up from about 7p to 12p over last 3 months

listed on Ausraillian Stock Market and London AIM

must be interesting to watch at least. DYOR then do it again to make sure I'm not dreaming.

check it out and ket me know what you think

cheers
SD

Ethel
Interesting news about Skye Pharma which I don't follow, so new to me. I normally do not follow pharma's at all on a general rule that they have too many extrinsic risk attaching (government regulation, unforeseen side effects, loss of patent/cheap generics and massive abortive r&d costs).

The thing I like about PSG is that it's not inventing new pharmaceuticals, but reinventing the chemical delivery method of old ones - cash generation level one. Then there are all the neutraceuticals which it is a few steps ahead of the crowd on using the same chemistry - like SEO has mutliple applications for its core technology so has PSG. Interesting breadth as well as depth to its prospects.

Hope Portugal is warmer than my office!

Brr Brr

SD

Interesting results issued today - SP up .5p. Looks good for 2005 progress.

SD

Encouraging news on the Phospha E anti-cholesterol trials causing a little tick up on the SP.



RNS Number:3458K
Phosphagenics Limited
31 March 2005

31 March 2005

Phosphagenics Limited

Phospha E significantly reduces animal blood cholesterol levels

Phosphagenics Limited today announced the results of successful animal trials
showing that treatment with Phospha E (Phosphagenics' unique vitamin E product)
reduced LDL-C (bad cholesterol) concentrations in blood by up to 40%. This
level of efficacy is unique for a supplement and is similar to that seen with
cholesterol lowering drugs that used the same animal model.

This work, conducted by Monash University at the Department of Biochemistry and
Molecular Biology, is part of the work necessary to progress Phospha E from test
tube to human trials.

"The current study extends the earlier positive in vitro findings and further
demonstrates the potential of Phospha E to prevent cardiovascular disease," said
Dr Esra Ogru, vice-president research & development.

These results indicate that Phospha E has the potential to reduce elevated
cholesterol, triglyceride and LDL levels in humans. The animal model chosen for
the trials is commonly used in cardiovascular research as it mimics many of the
properties observed clinically as part of the progression of human heart
disease, and it has been used with most of the currently marketed drugs that
lower blood lipids.

In the trials, mice were placed on a high cholesterol diet for eight weeks under
controlled conditions. Either Phospha E or regular Vitamin E was administered at
comparable doses on a daily basis starting four weeks after the commencement of
the high cholesterol diet.

Bad cholesterol (LDL-C) was reduced by up to 40% after two weeks of treatment
with Phospha E supplementation. There was no significant change in good
cholesterol levels (HDL-C) in these mice. Another heart disease risk factor,
plasma triglycerides, was also reduced by 44% after four weeks.

In marked contrast to Phospha E, no changes in blood lipid concentrations were
observed in mice fed with the regular Vitamin E. This is in line with the
results from other researchers reported in academic literature.

Heart disease is one of the major killers in Western societies. A number of
factors are instrumental in causing heart disease, including elevated
cholesterol. It has been estimated that heart disease costs Australia $3.7
billion a year and in the USA $100 billion.

A commercial form of the Phospha E product is sold in the USA and Phosphagenics
is working to extend the distribution globally.

For further information, contact Dr Esra Ogru, vice-president research and
development on 61 3 9605 5900 or 0402 080 846


This information is provided by RNS
The company news service from the London Stock Exchange
END

Good results on pre-clinical trials for transdermal delivery of peptides.

PSG has developed a radical new solution to a human-life requirement that is going to be with us for ever - effective water-soluble delivery of a massive range of drugs (from heart disease treament/prevention and diabetes to osteoporosis and VitaminE added drinks) which hitherto have only been deliverable in highly inefficient large doses which flood the body, with concommitant side effects, in order for the amount that reaches the affected area needing treatment to be sufficient.

This company is a little like SEO; once the technology - phosphorylation, briefly the chemical addition of phosphate groups to existing drugs to make them water-soluble - is fully established and authorised, its applications are almost endless across a wide range of pharma- and the new buzz-word neutra-ceutical applications.

The SP has been pretty inactive and I have no idea when it might start to wake up, but sometime between 1 to 3 years I am convinced this company will start to grow exponentially. I intend to be there for the fun.

sd




RNS Number:7724N
Phosphagenics Limited
21 June 2005

Phosphagenics Limited ("Phosphagenics") (ASX code: POH; AIM code: PSG) is
pleased to announce results of a preclinical trial in which its patented drug
delivery system, TPM-01, successfully delivered the bio-active fragment (1-34)
of human Parathyroid hormone through the skin.

Parathyroid hormone is a naturally occurring polypeptide gaining widespread
recognition in the treatment of osteoporosis. Current treatment involves daily
injection with the hormone.

Dr Esra Ogru, Phosphagenics' Vice President of Research & Development said that
this new product opportunity represented a valuable addition to Phosphagenics'
product pipeline and was an important step in the development of a comprehensive
transdermal platform technology.

"Peptides are a very important class of pharmaceutical compounds - insulin and
growth hormone are two other well known examples - that currently must be
delivered by injection. We are confident that our technology will effectively
deliver numerous peptides safely and painlessly through the skin."

"We intend to continue further development of transdermal delivery of
Parathyroid hormone and begin trials on the delivery of insulin and other
peptides using our technology".

"Phosphagenics had previously demonstrated that its technology was capable of
delivering a wide range of pharmaceutical compounds, including morphine,
testosterone, oestrogen and atropine through the skin. Parathyroid hormone was
the first peptide that we had tested so we were pleased with its success."

"Clearly, our platform technology has widespread application for the safe,
painless and effective delivery of many differing pharmaceutical compounds to
patients" said Dr Ogru.


A leading expert on osteoporosis, Professor Ego Seeman, from the Austin and
Repatriation Medical Centre, University of Melbourne and medical advisor to
Phosphagenics said the Company's animal trial results represented a significant
breakthrough as this agent has been shown to partly restore the structure of the
skeleton and reduce the risk of fractures.

"Osteoporosis, or fragile bone, is a major public health threat. It is estimated
that more than 40 million people in North America, Europe, Japan and Australia
are affected. About 40 per cent of women and 20 per cent of men in these regions
will suffer a fracture related to osteoporosis in their lifetime."

"Currently, Parathyroid hormone treatment must be delivered by injection once a
day using a special injection device. There is a need for a second generation
formulation such as a patch," said Professor Seeman.

Phosphagenics has filed a new patent application to protect its latest
discovery, bringing the total number of patents in its portfolio that have been
filed or granted to 21.

For further information please contact:

Associate Professor Andrew Vizard
Telephone: +61 3 9605 5900

www.phosphagenics.com

On a sombre day for London, PSG have published their July newsletter which makes interesting reading.

sd

http://www.phosphagenics.com

Ian - why doesn't the weblink icon work?

Large sell of 500k went through to day and the SP dipped .5p. Watch out everyone when the lock-in for directors ends on 29th July.

Although one or two may sell, my guess is they will all hold tight with a product and company this good and, when that is recognised by the market, we might start to see the progress this share deserves.

This company is to drug delivery and nutraceuticals what SEO is to packaging and frogpack - IM(not so)HO, of course.

sd

Interims announced today - nothing surprising.

REVIEW AND RESULTS OF OPERATIONS

For the 6 months ended 30 June 2005, the Company returned an after tax loss of
$1,959,467 (2004: $949,461). This is the first period that the Company has
reported its profit and loss figures on a consolidated basis, following its
purchase of Vital Health Sciences Pty Ltd in December 2004. This is also the
first period that the Company has reported in accordance with Australian
equivalents to International Financial Reporting Standards.

During the period, the Company continued with and accelerated its research
programme with the following important results:

- successfully delivering parathyroid hormone through the skin
- completion of a human trial showing that Phosphagenics technology can deliver therapeutic levels of
morphine through the skin
- completion of animal trials for its patented drug APA-01 showing that it has potential to prevent
atherosclerosis, the leading cause of heart disease in the western world
- completion of animal trials showing that Phospha E (Phosphagenic's unique vitamin E product) reduced
LDL-C (bad cholesterol) concentrations in blood by up to 40%, as well as significantly reducing levels of
plasma triglycerides, another heart disease risk factor.



The Company has also signed a letter of intent to supply Swisse Vitamins Pty Ltd
with its patented vitamin E phosphate (Phospha E) for sale to the dietary
supplement market in Australia, once regulatory approvals have been obtained.

You should also read the analyst's report by BBY dated 20th June 2005.

http://www.phosphagenics.com/main/investors_shareholders.htm

Their conclusion is the company is worth NPV of Aus$0.68 (28.5p) and even without the pharmaceuticals side, their nutraceuticals alone are worth NPV of Aus$0.29 (12.1p) compared to today's mid price of 10.5p, so the pharmaceuticals are in for free.

The SP has been up and down over the last year and is currently trading below its 200dma, but seems to have reached a plateau of support at 10.5p. You need patience, with their 3 main pharma products estimated to launch in 2007, 2008 and 2009 respectively. But this really is a company worth watching and taking the time to realise value. Recommended by RHPS.

One to tuck away and forget.

sd (aka the lone wolf)

Stockdog

Brilliant write up in equity development. Reminds me when i use to be on the chp thread all by myself, nevermind

forest - what's equity development - is there a website or better a link?

http://www.equitydevelopment.co.uk/client/index.html

SD, you will have to sign in to get article free site.

hi forest - thanks

not many followers here, but I do think the applications of their basic patents are as wide for the pharma/nutra-ceuticals world as SEO is for packaging. surprised not more interest yet, but remains a good time to keep buying IMHO.

sd

chart: http://www.asx.com.au/asx/research/chartsSearchResult.jsp?asxCode=POH&TimeFrame=D6&compare=index&indices=XJO

Above Aus Stock Exchange

Below Aus discussion site
http://www.hotcopper.com.au/

Note, PSG is POH in Aus.

Phosphagenics Limited
21 October 2005




21 October 2005



The Manager
Company Announcements Office
The Australian Stock Exchange Limited


Dear Sir



re : Second Study links Phospha E to healthy cardiovascular function



ASX and AIM listed biotechnology company Phosphagenics Limited ('Phosphagenics')
today announced results of an animal study that confirms an earlier study
suggesting that its patented product Phospha E may proactively benefit
cardiovascular health. In this new animal study, Phospha E significantly reduced
LDL-C (so-called bad cholesterol), triglycerides, and plaque formation.



The study data showed that this unique form of vitamin E lowered bad cholesterol
concentrations in blood by up to 44% and triglycerides by up to 51% in mice fed
normal diets. When fed high cholesterol diets, Phospha E significantly reduced
plaque formation in the aorta by 58%. In contrast, regular vitamin E had no
significant effect on plaque formation, or cholesterol levels. These results
confirm the earlier animal study indicating that Phospha E may have the
potential to yield healthier levels of total cholesterol, triglycerides and
LDL-C in humans. The animal model chosen for the trials is commonly used in
cardiovascular research as it mimics many of the properties observed clinically
in humans.

'We are encouraged that these results support the earlier animal study. Based on
these animal studies, as well as earlier in vitro studies, we are confident in
the potential of Phospha E to support cardiovascular health in humans,' said Dr
Esra Ogru, Executive Director of Research and Development.

'We are very pleased with these results as we continue to push forward with
research into the benefits of Phospha E. Phosphagenics intends to commence
clinical trials in humans to provide further support for the product's health
benefits, including its effect on cardiovascular health,' said Dr Ogru.



Phosphagenics has a licensing agreement with Zila Nutraceuticals, Inc., USA, a
wholly owned subsidiary of Zila, Inc., for the production and distribution of
its product under the Ester E brand in the United States, Canada and Indonesia.
Ester E is currently sold widely in the United States through retail chains and
health food stores

Nice one Forest - this company will be massive one day, but it will take a lot of hard work and patiience to bring all their products to market. Until then, no point in tracking the SP - just sit tight for 2-5 years IMHO.

sd

Good news.


Phosphagenics Limited signs Development Agreement with ALZA Corporation


Biotechnology company Phosphagenics Limited ('Phosphagenics') (ASX Code: POH;
AIM Code: PSG) today announced it has entered into a development agreement with
ALZA Corporation (ALZA).


ALZA is a leading drug delivery company with a broad range of technology
platforms. Under the terms of the agreement, ALZA will fund tests to determine
the feasibility of delivering a number of compounds nominated by ALZA using
Phosphagenics' patented transdermal delivery system, TPM-01.


Dr Esra Ogru, Executive Director of Research & Development for Phosphagenics,
said, 'Phosphagenics' transdermal technology is globally-competitive and
uniquely safe and effective, and has the potential to be applied to an
extraordinarily broad range of drugs.


'Our technology has previously been tested on a number of drugs, and has
successfully delivered insulin, parathyroid hormone, fentanyl, morphine,
estradiol, testosterone and atropine across animal skin,' added Dr Ogru.


Phosphagenics' transdermal technology, TPM-01, is a non-invasive, patient-
friendly gel applied to the skin. In April this year, TPM-01 was shown to be
effective in delivering morphine into the bloodstream through human skin in a '
proof of concept' Phase I clinical trial. Phase I trials on the transdermal
delivery of insulin with TPM-01 are planned to start in the first quarter of
2006.

Anyone know anyting about ALZA? Which country is it based in? Waht's its track-record with what other related products?

Sorry, no time to DMOR today!

sd

sd
just did a quick google search, loads of info. As you i do not have the time at the moment, be back later.

Taken from another BB.

an update by CS as well........

Phosphagenics Development agreement with Alza Corporation

Phosphagenics has entered into a development agreement with Alza Corporation, a leading drug delivery company and a subsidiary of Johnson & Johnson. Under the terms of the agreement Alza will test a range of its drugs with TPM-01, Phosphagenics transdermal drug delivery platform.

Analysis
This is a very important deal for Phosphagenics, as it provides validation for its transdermal platform technology, TPM-01. As part of the development agreement Alza will fully fund testing of TPM-01 with a broad range of drugs. Any positive outcomes of the tests should lead to a full clinical development programme. We believe that this should trigger milestone payments and a future royalty stream for Phosphagenics.

Action

Phosphagenics has already demonstrated that it can deliver a broad range of drugs and chemicals across animal skin, including insulin, parathyroid hormone, fentanyl, estrodiol and testosterone. The company has also successfully delivered Morphine transdermally using TPM-01; therefore we are confident that the technology will be used successfully with some of the drugs that Alza will test. We expect that there will be further newsflow from this collaboration in 2006.

This relationship with Alza is very valuable for Phosphagenics. The company is yet to license a partner for its lead product TPM-01/Morphine and we believe that Alza could be a potential partner.

The upside therefore possible from the transdermal work currently being undertaken is significant. We eagerly await the results of Phase II data on the morphine formulation. More importantly the work relating to cholesterol lowering and the inhibition of plaque formation in arteries offers significant upside. The shares are clearly undervalued. Our price target in valuation terms remains 170 million

sd
as requested, owned by Johnson & Johnson

ALZA Corporation is the leading provider of drug delivery solutions with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies. ALZA partners with pharmaceutical and biotechnology companies to develop and manufacture pharmaceutical products that enhance healthcare for millions of patients worldwide.

Founded in 1968 by Dr. Alejandro Zaffaroni, ALZA has over 35 years of experience in scientific innovation. ALZA technology has been incorporated in 30 commercialized products marketed in more than 80 countries. More than 3,000 US and foreign patents are active or pending.



A Problem-Solving Approach
ALZA provides value to our partners in all phases of product development, from initial concept, through manufacturing and commercialization. Many of our collaborations begin in the early phases of product development, using our pharmacologic discovery process to identify optimal delivery profiles. This process pushes the boundaries of drug delivery, and yields highly attractive options for partner companies to commercialize novel therapies.



A Center for Scientific Excellence
Our expertise spans the physical sciences, biology, engineering, clinical research and pharmacology. As a Johnson & Johnson company, ALZA extends a global reach and is dedicated to developing unmatched scientific solutions to some of the world's most critical healthcare needs.



Inventing the Future
As new compounds emerge from biotechnology and genetic research, ALZA technologies continue to evolve, providing unique delivery platforms that extend the potential of important new therapies. Year after year, we deliver results that benefit healthcare and expand market opportunities for our pharmaceutical partners

forest
Interesting - thanks
sd